ACAT1 and carcinoma: A combined therapy of the ACAT inhibitor avasimibe plus an anti-PD-1 antibody showed a delightful effect of suppressing the tumor development and progression [13], which provided a whole new perspective for us to perform medical work, using specific tumor inhibitor of BGN and an anti-PD-1 antibody to fight with carcinoma.